Clinical Scorecard: Preservation of Vision in GA in ARCHER Trial Continues Evaluation in ARCHER II
At a Glance
| Category | Detail |
|---|---|
| Condition | Geographic Atrophy (GA) |
| Key Mechanisms | ANX007, a compound produced by Annexon, is being studied for its potential to preserve vision in GA patients. |
| Target Population | Patients with geographic atrophy and visual acuity of 20/100 or better. |
| Care Setting | Ophthalmology clinics conducting clinical trials. |
Key Highlights
- ANX007 showed a significant reduction in 15-letter loss of vision compared to sham.
- Number needed to treat (NNT) is 7 to prevent 1 patient from significant vision loss.
- Phase 3 trial focuses on visual acuity as a primary endpoint.
- ANX007 provides approximately 60% protection of photoreceptors in the central fovea.
- Trial allows both center-involved and noncenter-involved lesions.
Guideline-Based Recommendations
Diagnosis
- Assess visual acuity and GA lesion size.
Management
- Consider ANX007 for patients with GA to preserve vision.
Monitoring & Follow-up
- Follow visual acuity and changes in GA lesion size over time.
Risks
- Exclude patients with a history of choroidal neovascularization in the study eye.
Patient & Prescribing Data
Patients with geographic atrophy and visual acuity of 20/100 or better.
ANX007 is administered via intravitreal injection.
Clinical Best Practices
- Monitor patients for visual acuity changes during treatment.
- Evaluate the ellipsoid zone for photoreceptor protection.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
